It has been proposed that cyclic AMP inhibits platelet reactivity: (a) by preventing agonist-induced phosphoinositide hydrolysis and the resultant formation of 1,2-diacylglycerol and elevation of cytosolic free 
INTRODUCTION
Human platelet responsiveness is controlled by the opposing actions of stimulatory and inhibitory secondmessenger molecules. Ca2+ and 1,2-diacylglycerol (DAG) act synergistically to promote platelet activation (Michell, 1983) , whereas 3',5'-cyclic adenosine monophosphate (cyclic AMP) acts as an inhibitory modulator (Feinstein et al., 1981) . Production of DAG and elevation of the cytoplasmic free Ca2+ concentration ([Ca2+] 1) could both occur as a consequence of agonist-induced phosphoinositide hydrolysis. The phospholipase Ccatalysed hydrolysis of phosphatidylinositol 4,5-bisphosphate [Ptdlns(4,5)P2] directly yields DAG and inositol 1,4,5-trisphosphate [Ins(1, 4, 5) PJ, which can release Ca2+ from intracellular stores (O'Rourke et al., 1985) . However, in the presence of the normal physiological concentration of extracellular free Ca2+
(1 mM), agonist-induced elevation of [Ca2+] i derives predominantly from Ca2+ influx (Hallam et al., 1984) . The role, if any, of phosphoinositide hydrolysis in this process remains to be determined (Berridge, 1984) . Elevation of platelet cyclic AMP concentration by inhibitory platelet agonists (e.g. PGI2, PGD2 and adenosine) results in the suppression ofplatelet activation (Feinstein et al., 1981) . Besides inhibiting the cellular responses (Hawiger et al., 1980; Feinstein et al., 1981) initiated after exposure to stimulatory agonists, the inhibitory effects of cyclic AMP are also evident on the transduction processes that link receptor occupancy to cellular activation (Kaser-Glanzmann et al., 1977; Fox et al., 1979; Feinstein et al., 1983; Sano et al., 1983; Lapetina, 1984) .
In order to determine the relationship between elevation of cyclic AMP content and the degree of inhibition of distinct platelet responses, we examined the effects of PGD2 on shape change, aggregation, ATP secretion, elevation of [Ca2+]i and stimulation of [32P]PtdA formation (an index of phosphoinositide hydrolysis and DAG formation) induced in human platelets by submaximal concentrations of PAF.
EXPERIMENTAL Methods
Blood was obtained from healthy volunteers who denied taking drugs known to affect platelet function, and platelet-rich plasma (PRP) was prepared (Pollock et al., 1984) . In most cases (except phospholipid studies) the Vol. 232 Abbreviations used: DAG, 1,2-diacylglycerol; [Ca2+]1, cytosolic free Ca2+ concentration; Ptdlns(4,5)P2, phosphatidylinositol 4,5-bisphosphate; Ins(1,4,5)P,, inositol 1,4,5-trisphosphate; PG, prostaglandin; PtdA, phosphatidic acid; PAF, platelet-activating factor (l-O-hexadecyl-2-acetylsn-glycero-3-phosphocholine); PRP, platelet-rich plasma; IrO, concentration causing 50% inhibition.
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(10-15 /M; 30-40 min; 37 C). Quin2-labelled platelets were separated from plasma containing extraneous dye by gel filtration on columns of Sepharose 2B equilibrated with a modified Hepes-buffered Tyrode's solution (Pollock et al., 1984) . The quin2 content of the platelets was around 1 mmol/litre of cell water. Immediately before use the external free Ca2+ concentration was adjusted either to 1 mm (by addition of CaCl2) or to about 1-10 nM (by addition of EGTA).
[Ca2+], was measured as described previously (Maclntyre et al., 1985) . Shape change, aggregation and ATP secretion were monitored in parallel with [Ca2+] i by using subsamples of the quin2-loaded gel-filtered platelets. Platelet shape change was monitored photometrically in stirred (700 rev./min) platelet suspensions (0.6 ml; 37°C) by using a Mallin clinical aggregation recorder. In these studies, to decrease the extracellular [Ca2+] and hence prevent both platelet aggregation and Ca2+ influx, EGTA (4 mM) was added to each platelet sample 60 s before agonist addition. Aggregation and ATP secretion were monitored simultaneously in stirred (700 rev./min) platelet samples (0.45 ml; 37°C) by using a Chronolog Corp. luminescence aggregometer. Incubations were for 90 s with PGD2 or vehicle [saline (154 mM-NaCl)] before the addition of a submaximal concentration of PAF. The optimal PAF concentration (i.e. that which elicited around 70% of maximum response) was determined at the start of each experiment and varied from 18 to 180 nM-PAF.
Phospholipid studies were carried out essentially as described previously (Pollock et al., 1984) . PGD2 or saline was added for 90 s and reactions were initiated by addition of PAF (18 nM). After 30 s, reactions were terminated (Pollock et al., 1984) and lipids were extracted, dried at 40°C under N2, separated by two-dimensional t.l.c. (Yavin & Zutra, 1977) and detected by exposure to iodine vapour. The spots corresponding to PtdA were scraped into vials and counted for radioactivity in a liquid-scintillation counter. Note that under the conditions of these experiments, changes in [32P]PtdA reflect changes in PtdA concentration and the DAG precursor of PtdA is most probably derived via hydrolysis of phosphoinositides (MacIntyre & Pollock, 1983) .
In most cases, for the estimation of cyclic AMP concentration, subsamples of platelets were removed from the fluorimeter or aggregometer cuvettes, or in phospholipid studies from samples processed in parallel, except that [32P]P, was omitted, before the addition of PAF and were added to 2 vol. of ethanol. After addition to ethanol, the samples were vortex-mixed, left at room temperature for 5 min, centrifuged (10 min; 500 g; room temperature) and the supernatant removed and evaporated at 60 'C. The dried samples were resuspended in 50 mM-sodium acetate buffer, pH 6.2, and the cyclic AMP content was determined by radioimmunoassay (Brooker et al., 1979 International, and carrier-free [32P]P1 was supplied by the Regional Isotope Dispensary, Western Infirmary, Glasgow, Scotland, U.K. EGTA was obtained from Sigma. All other reagents were of the highest purity available and were obtained as previously described (Pollock et al., 1984) .
RESULTS
In confirmation of previous reports (MacIntyre & Pollock, 1983; Fouque & Vargaftig, 1984; Hallam et al., 1984) , preliminary studies established that PAF (1-180 nM) The basal level of platelet cyclic AMP (6.9 +0.4 pmol/108 cells; mean+S.E.M., n = 6) was augmented in a concentration-dependent manner after exposure to PGD2 (Fig. la) (Figs. If and ig) . The degree of inhibition of the various PAF-induced responses could be correlated with the rise in cyclic AMP content elicited by PGD2 in the same (or parellel samples for [32P]PtdA formation) platelet samples (Fig. 2) . PAF-induced ATP secretion and aggregation were very susceptible to small increments in the cyclic AMP content, both being abolished by a doubling in the cyclic AMP content (Fig. 2) . However, [32P]PtdA formation, shape change and elevation of [Ca2+], were less susceptible: maximal inhibition of these responses did not occur until the cyclic AMP content had been elevated by more than 10-fold (Fig. 2) .
DISCUSSION
PAF is believed to activate human platelets by mechanisms dependent upon DAG and elevated [Ca2+] , and consequent upon receptor-linked phosphoinositide hydrolysis (Maclntyre et al., 1985) . PGD2 causes elevation of platelet cyclic AMP concentration and inhibition of platelet function (Smith et al., 1976; De Gaetano et al., 1982) , presumably mediated by cyclic AMP-dependent protein kinase. It has been proposed that elevated cyclic AMP concentrations inhibit Dlatelet function by suppressing the production of the stimulatory second-messenger molecules Ca2+ (Feinstein et al., 1983) and DAG (Lapetina, 1984 were analysed using Student's t-test: *P < 0.05; **P < 0.005. when added after stimulatory agonists (Feinstein et al., 1983) . This effect might be mediated by increased Ca2+ sequestration and/or extrusion (Feinstein et al., 1983; Kaser-Glanzmann et al., 1977) . In addition, cyclic AMP-dependent protein kinase has been shown to inhibit platelet myosin-light-chain kinase activity, a Ca2+-activated enzyme (Hathaway et al., 1981) . Hence cyclic AMP can modify the rate of production and inactivation of the stimulatory second messengers and can antagonize their effects to prevent or reverse agonist-induced platelet activation.
In the present study we (Steen & Holmsen, 1984) . However, those studies may not be directly comparable, since both the stimulatory (ADP) and inhibitory (PGE1, adenosine) agonists used differed from those employed in the present study. Indeed, there is evidence that different agonists show differential sensitivity to inhibition by cyclic AMP (Krishnamurthi et al., 1984; .
Human platelets contain a single population of receptors for PGD2 that are coupled to adenylate cyclase activation and consequent elevation of the platelet cyclic AMP content, to approx. 100-fold the basal level (Smith et al., 1976; Siegl et al., 1979) . The differential sensitivity of the various PAF-induced platelet responses to inhibition by PGD2 reflects, in part, the 'receptor reserve' of the system: that is, a low degree of PGD2 receptor occupancy, which elicits a modest increment in platelet cyclic AMP content (100%), is sufficient to abolish PAF-induced aggregation and ATP secretion, whereas a higher degree of receptor occupancy that elicits a moderate increase in cyclic AMP content (10-fold) is required to abolish shape change, phosphoinositide hydrolysis and Ca2+ flux. The effects of cyclic AMP are thought to be mediated by cyclic AMP-dependent protein kinase, of which two types exist in platelets (Nimmo & Cohen, 1977; Salama & Haslam, 1984) . Evidence in numerous cell types would indicate that only small increments in cyclic AMP concentration are necessary to stimulate maximally cyclic AMP-dependent protein kinase (Flockhart & Corbin, 1982) . If this is also the case in human platelets, as is indicated by our preliminary findings (M. Bushfield & D. E. Maclntyre, unpublished work) , then the bulk of the cyclic AMP generated by platelets in response to adenylate cyclase stimulants is not coupled to activation of cyclic AMP-dependent protein kinases. This could indicate that cyclic AMP and/or cyclic AMP-dependent protein kinase are compartmentalized within platelets, and that the major cyclic AMP compartment is redundant in terms of regulating platelet reactivity. Indeed, there is evidence for compartmentalization ofcyclic AMP and cyclic AMP-binding proteins in platelets (Lyons, 1980; Hashimoto, 1983) .
The reasons underlying the differential sensitivity of the various platelet responses to increase in cyclic AMP concentration and the role of cyclic AMP-dependent protein kinase in the control of platelet responsiveness require further investigation. We suggest that a major component of inhibition of PAF-induced platelet activation by cyclic AMP-dependent processes is mediated by suppression ofcertain aspects of the activation process that occur distal to the formation or elevation of the stimulatory second messengers, Ca2+ and DAG.
